Unknown

Dataset Information

0

Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape.


ABSTRACT: Tar DNA binding (TDP)-43 proteinopathy, typically described as cytoplasmic accumulation of highly modified and misfolded TDP-43 molecules, is characteristic of several neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and limbic-predominant age-related TDP-43 encephalopathy (LATE). TDP-43 proposed proteinopathies include homeostatic imbalance between nuclear and cytoplasmic localization, aggregation of ubiquitinated and hyper-phosphorylated TDP-43, and an increase in protein truncation of cytoplasmic TDP-43. Given the therapeutic interest of targeting TDP-43, this review focuses on the current landscape of strategies, ranging from biologics to small molecules, that directly target TDP-43. Antibodies, peptides and compounds have been designed or found to recognize specific TDP-43 sequences but alleviate TDP-43 toxicity through different mechanisms. While two antibodies described here were able to induce degradation of pathological TDP-43, the peptides and small molecules were primarily designed to reduce aggregation of TDP-43. Furthermore, we discuss promising emerging therapeutic targets.

SUBMITTER: Francois-Moutal L 

PROVIDER: S-EPMC8341936 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4279453 | biostudies-other
| S-EPMC6728177 | biostudies-literature
| S-EPMC5580514 | biostudies-literature
| S-EPMC8070438 | biostudies-literature
| S-SCDT-EMBOJ-2021-108443 | biostudies-other
| S-EPMC4404432 | biostudies-literature
| S-EPMC7924408 | biostudies-literature
| S-EPMC2478749 | biostudies-literature
| S-EPMC4478251 | biostudies-literature
| S-EPMC7040037 | biostudies-literature